论文部分内容阅读
目的评价胰激肽原酶肠溶片联合甲钴胺注射液治疗2型糖尿病周围神经病变(DPN)的疗效。方法纳入2012年1月-12月住院的84例DPN患者,随机分为治疗组和对照组,每组42例。治疗组采用胰激肽原酶+甲钴胺治疗,胰激肽原酶3次/d,120 U/次,口服甲钴胺1次/d,1 mg/次,静脉滴注;对照组单用甲钴胺治疗,甲钴胺静脉滴注1次/d,1 mg/次;两组均治疗14 d。结果治疗组显效22例,有效19例,无效1例;对照组显效8例,有效22例,无效12例;两组比较差异有统计学意义(P<0.01)。两组治疗后的神经传导速度均较治疗前有所改善,治疗组治疗后的神经传导速度改善优于对照组(P<0.01),治疗过程中无明显不良反应。结论胰激肽原酶肠溶片联合甲钴胺注射液对DPN的疗效优于单用甲钴胺。
Objective To evaluate the efficacy of pancreatic kallikrein enteric-coated tablets combined with mecobalamin in the treatment of type 2 diabetic peripheral neuropathy (DPN). Methods Eighty-four patients with DPN admitted to hospital from January 2012 to December 2012 were randomly divided into treatment group and control group, with 42 cases in each group. Treatment group was treated with pancreatic kallikrein + mecobalamin, pancreatic kallikrein 3 times / d, 120 U / times, oral mecobalate 1 times / d, 1 mg / times, intravenous drip; control group Mecobalamin treatment, mecobalamin intravenous infusion 1 / d, 1 mg / time; both were treated for 14 days. Results In the treatment group, 22 cases were markedly effective, 19 cases were effective and 1 case was ineffective. In the control group, 8 cases were markedly effective, 22 cases were effective and 12 cases were ineffective. There was significant difference between the two groups (P <0.01). The nerve conduction velocity of the two groups after treatment was better than that before treatment, and the improvement of nerve conduction velocity after treatment in the treatment group was better than that in the control group (P <0.01). There was no obvious adverse reaction during the treatment. Conclusions The combination of pancreatic kallikrein enteric-coated tablets and mecobalamin is better than mecobalamin for DPN.